Grants and Contributions:
Title:
In Vivo Validation of Fusogenix Formulations Optimized for Delivery of Genetic Medicines to the Trabecular Meshwork of the Eye
Agreement Number:
1029894
Agreement Value:
$250,000.00
Agreement Date:
Apr 1, 2025 - Mar 31, 2026
Description:
In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the trabecular meshwork of the eye to treat ophthalmological diseases. The project will validate previously optimized trabecular meshwork formulations combined with the pharma partners mRNA cargo and Entos cargoes including DNA in small and large animal models.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5J 4P6
Reference Number:
172-2025-2026-Q1-1029894
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
816561112
Recipient Type:
For-profit organization
Recipient's Legal Name:
Entos Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710